Randomized Trialmoderate evidence
Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer's disease: a phase 1b, randomized, double-blind trial.
Nature medicine·July 15, 2026·PMID 42458012
Why it mattersAlzheimer's disease progression is linked to unresolved neuroinflammation, and this trial provides first-in-human evidence that transient systemic PD-L1 blockade is safe and may engage relevant biomarkers, opening a novel immunomodulatory approach for early AD.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled